Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)
Public ClinicalTrials.gov record NCT00931606. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the percentage of participants in each sotatercept dose regimen who achieve a hematopoietic response during the treatment period including up to 2 months after the last dose of sotatercept treatment of chemotherapy-induced anemia (CIA) in participants with metastatic breast cancer. Hematopoietic response was defined as an increase in hemoglobin concentration of ≥ 1 g/dL relative to baseline for 28 consecutive days during the treatment period including up to 2 months after the last dose of sotatercept in the absence of red blood cell (RBC) transfusion or treatment with an erythropoiesis-stimulating agent (ESA).
Study identification
- NCT ID
- NCT00931606
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 1, 2009 (Actual)
- Primary completion
- Nov 18, 2010 (Actual)
- Completion
- Nov 18, 2010 (Actual)
- Last update posted
- Sep 13, 2023
2009 – 2010
United States locations
- U.S. sites
- 28
- U.S. states
- 20
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site | Sedona | Arizona | — | — |
| Investigative Site | Hot Springs | Arkansas | — | — |
| Investigative Site | Beverly Hills | California | — | — |
| Investigative Site | Corona | California | — | — |
| Investigative Site | Fountain Valley | California | — | — |
| Investigative Site | Montebello | California | — | — |
| Investigative Site | Riverside | California | — | — |
| Investigative Site | Denver | Colorado | — | — |
| Investigative Site | Boynton Beach | Florida | — | — |
| Investigative Site | Hinsdale | Illinois | — | — |
| Investigative Site | Evansville | Indiana | — | — |
| Investigative Site | Wichita | Kansas | — | — |
| Investigative Site | Baltimore | Maryland | — | — |
| Investigative Site | Grand Rapids | Michigan | — | — |
| Investigative Site | Tupelo | Mississippi | — | — |
| Investigative Site | Kansas City | Missouri | — | — |
| Investigative Site | Nyack | New York | — | — |
| Investigative Site | Goldsboro | North Carolina | — | — |
| Investigative Site | High Point | North Carolina | — | — |
| Investigative Site | Winston-Salem | North Carolina | — | — |
| Investigative Site | Bismarck | North Dakota | — | — |
| Investigative Site | Middletown | Ohio | — | — |
| Investigative Site | Philadelphia | Pennsylvania | — | — |
| Investigative Site | Charleston | South Carolina | — | — |
| Investigative Site | Austin | Texas | — | — |
| Investigative Site | Dallas | Texas | — | — |
| Investigative Site | Tyler | Texas | — | — |
| Investigative Site | Lacey | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00931606, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 13, 2023 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00931606 live on ClinicalTrials.gov.